1. Volume 64, Issue 6, Pages 1428-1445 (June 2016)
Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015 
Johannes Wiegand, Florian van Bömmel, Andrés Duarte-Rojo, José Altamirano, Juan G. Abraldes, Augusto Villanueva, Thomas Berg 
Journal of Hepatology 
Volume 64, Issue 6, Pages (June 2016)
DOI: /j.jhep
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
Characteristics of RG-101 (according to van der Ree, The Liver Meeting 2015).
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

3. Fig. 2
Scheme of the HBV life cycle including targets for new drugs and new HBV biomarkers presented during the Liver Meeting Some antiviral drugs target the HBV life cycle as polymerase inhibitors (1), core assembly inhibitors (2), siRNAs (3) or at HBV secretion as nucleic acid polymers (4). A different approach is immune stimulation via TLR-7 or by therapeutic vaccine (5). Degradation of cccDNA is pursued based on the CRISPR/Cas9 system (6). New biomarkers being assessed for their clinical use include HBV RNA, of which the composition in serum is still under research, and HBV core related antigen, which binds to three different serum proteins of HBV (7).
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions